Management Team
Yuling Luo, Ph.D., Founder, President & Chief Executive Officer
Dr. Luo is an entrepreneur with more than 14 years of start-up experience in leadership and innovation. Before ACD, Dr. Luo was a founder of Panomics (previously named Genospectra before its acquisition of Panomics), a life science company that was acquired by Affymetrix in 2008. At Panomics, Dr. Luo served various roles including Vice President, Functional Genomics and Chief Scientific Officer and he led the development and launch of all of its flagship product lines. Prior to Panomics, Dr. Luo was one of the earliest senior scientists at Exelixis, where he led a team to identify and validate novel therapeutic targets. Dr. Luo has published many research papers in top peer-reviewed journals. His inventions are the subject of over a dozen patents and patent pending applications. Dr. Luo received his doctorate in biochemistry from Case Western Reserve University and conducted post-doctoral research at the University of Pennsylvania.
Steve Chen, Ph.D., Founder, Chief Operating Officer
Dr. Chen brings to ACD over 14 years’ experience in technology innovation and management. Before ACD, Dr. Chen co-founded Genospectra with Dr. Luo, served as its Chief Technology Officer and led the development of its microarray instrumentation systems. Prior to Genospectra, Dr. Chen was an Assistant Professor at University of Maryland, College Park where he conducted research in the field of optical sensors and instrumentation. His research work has resulted in several dozen peer-reviewed journal publications and 6 issued patents. Dr. Chen holds a Ph.D. in Electronic Engineering from University of London.
Xiao-Jun Ma, Ph.D., Chief Scientific Officer
Dr. Ma is a leader in genomic research and molecular diagnostics for personalized medicine. Applying his multi-disciplinary expertise in molecular biology, bioinformatics and statistics, Dr. Ma has a proven track record of developing molecular signatures for cancer diagnostics and identifying novel drug targets for over 14 years. Prior to joining ACD, Dr. Ma was Vice President of R&D/Biostatistics in bioTheranostics (formerly AviaraDx and Arcturus Bioscience), a bioMérieux company, where he led efforts to successfully develop several advanced molecular diagnostic tests in cancer classification and prognosis. Prior to bioTheranostics, Dr. Ma held senior bioinformatics positions at Johnson & Johnson Pharmaceutical Research Institute and Monsanto/Searle. He received his doctorate training in biochemistry at Case Western Reserve University and the University of Iowa and post-doctoral training in molecular genetics at the University of California, Los Angeles.
Christopher Bunker, Ph.D., M.B.A., Senior Director, Business Development
Dr. Bunker brings ten years of experience in business development with pharmaceutical/biotechnology organizations. Prior to joining ACD, Dr. Bunker was Director of Business Development at Cell Signaling Technology, Inc. (CST), where he helped build the company from its initial spin-out to a $100MM business. Before CST, Dr. Bunker pursued cancer research at Genome Therapeutics Corp. Dr. Bunker received a Ph.D in Biological Chemistry from Harvard University and a M.B.A. from the executive program of Boston University. He received post-doctoral training in cancer molecular biology at University of California, San Francisco.
.